Recent Company News

• 03:56 AM ET Aug 19, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (46 total)

• 04:19 AM ET Aug 18, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (50 total)

• 05:51 AM ET Jul 24, 2026
  

  Transcript Intelligence: Almirall Q2 Earnings Guidance

• 05:51 AM ET Jul 24, 2026
  

  Transcript Intelligence: Almirall Q2 Earnings Themes

• 05:51 AM ET Jul 24, 2026
  

  Transcript Intelligence: Almirall Q2 Earnings Q&A

• 04:10 AM ET Jul 24, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:08 AM ET Jul 24, 2026
  

  Almirall reports H1 normalised net income €42.4M vs FactSet €41.1M [3 est, €38-43.3M]; guides FY26 (€11.06, 0.00)

• 04:04 AM ET Jul 20, 2026
  

  Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older (€10.78, +0.10)

• 02:16 AM ET Jul 16, 2026
  

  Almirall upgraded to buy from hold at Bestinver Securities (€10.66, 0.00)

• 06:23 PM ET Jun 09, 2026
  

  FDA approves Lilly's EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis ($1144.68, 0.00)